omarigliptin
Small moleculeexperimental
Omarigliptin (MK-3102) is a potent, long-acting oral antidiabetic drug of the DPP-4 inhibitor class used for once-weekly treatment of type 2 diabetes and currently under development by Merck & Co. It inhibits DPP-4 to increase incretin levels, which inhibit glucagon release, which in turn increases insulin secretion, decreases gastric emptying and decreases blood glucose levels. — Wikipedia
Clinical trial activity
27 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
17
Phase 3
13
Phase 4
1
Earliest trial started Mar 1, 2010 (NCT01088711)
Timeline
Indications
Approved for
Mechanism of action
- Dipeptidyl peptidase IVINHIBITOR
DPP4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CS(=O)(=O)n1cc2c(n1)CN([C@H]1CO[C@H](c3cc(F)ccc3F)[C@@H](N)C1)C2- Mol. weight
- 398.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaOmarigliptin ↗
- ChEMBLCHEMBL2105762 ↗
Also known as
- 2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4h)-yl)tetrahydro-2h-pyran-3-amine
- marizev
- mk3102
- mk-3102
- mk-3102
- mk-3102
- mk-3102
- mk-3102
- mk-3102
- omarigliptin
- omarigliptin
- omarigliptin
- omarigliptin
- omarigliptin
- omarigliptin
- omarigliptin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06703268 | Phase 2 | Jan 15, 2024 | Haisco Pharmaceutical |
| NCT05497297 | Phase 1 | Aug 4, 2022 | Haisco Pharmaceutical, Peking University |
| NCT06003088 | Phase 1 | Jun 15, 2022 | Haisco Pharmaceutical |
| NCT04727580 | Phase 2 | Mar 29, 2021 | Haisco Pharmaceutical |
| NCT04564872 | Phase 3 | Nov 13, 2020 | Haisco Pharmaceutical |
| NCT04540016 | Phase 1 | Oct 15, 2020 | Haisco Pharmaceutical, Soochow University, Suzhou Medical College |
| NCT04556851 | Phase 3 | Sep 29, 2020 | Haisco Pharmaceutical |
| NCT06084156 | Phase 1 | Aug 10, 2019 | Haisco Pharmaceutical |
| NCT06059326 | Phase 2 | Jan 22, 2019 | Haisco Pharmaceutical |
| NCT05983289 | Phase 1 | May 8, 2018 | Chinese Academy of Medical Sciences, Haisco Pharmaceutical |
| NCT03362398 | N/A | Nov 20, 2017 | British University In Egypt |
| NCT02906709 | Phase 4 | Oct 17, 2016 | Merck |
| NCT01863667 | Phase 3 | Jul 1, 2013 | Merck |
| NCT01841697 | Phase 3 | Jun 1, 2013 | Merck |
| NCT01814748 | Phase 3 | May 1, 2013 | Merck |
| NCT01767688 | Phase 1 | Jan 1, 2013 | Merck |
| NCT01755156 | Phase 3 | Jan 1, 2013 | Merck |
| NCT01717313 | Phase 3 | Dec 1, 2012 | Merck |
| NCT01703208 | Phase 3 | Oct 5, 2012 | Merck |
| NCT01698775 | Phase 3 | Oct 1, 2012 | Merck |
Showing 20 of 27 trials
Page 1 / 2
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 16 | 16 | 4 | 2010 |
| Haisco Pharmaceutical | For profit | 10 | 10 | 3 | 2018 |
| British University In Egypt | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Soochow University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Suzhou Medical College | Academic/Hospital | 1 | 0 | 1 | 2020 |
7 organizations
Page 1 / 1